Considering the role of BRAF mutations in the pathogenesis of melanoma, treatments mostly target BRAF, MAPK, and ERK in order to dampen the deleterious effects of the constitutively active BRAF/MEK/ERK cascade [13]. This evidence concerns the gene MAP2K7 and melanoma.